Drug details

Elzonris (tagraxofusp-erzs injection)

type of Antineoplastics, Other

Elzonris (tagraxofusp-erzs) is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• itching,
• rash,
• tiredness,
• dizziness,
• mouth sores,
• decreased urination,
• thirst,
• weight gain
• sudden warmth or tingly feeling,
• sudden swelling, and

The following drugs are related to Elzonris, either as a replacement or used together:

• Adcetris (brentuximab vedotin)
• Afinitor (everolimus tablets)
• Afinitor Disperz (everolimus tablets)
• Alecensa (alectinib capsules)
• Alimta (pemetrexed)
• Alkeran (melphalan)
• Alkeran Injection (melphalan hcl injection)
• Alunbrig (brigatinib tablets)
• Belrapzo (bendamustine hydrochloride injection)
• Maxidex Ointment (dexamethasone sodium phosphate ophthalmic)
• Gleevec (imatinib mesylate)
• Ibrance (palbociclib capsules for oral administration)
• Jakafi (ruxolitinib)
• Lenvima (lenvatinib capsules)
• Lonsurf (trifluridine and tipiracil tablets)
• Lynparza (olaparib capsules for oral administration)
• Otrexup (methotrexate injection)
• Tysabri (natalizumab)
• Oncaspar (pegaspargase)
• Rituxan Hycela (rituximab and hyaluronidase human injection)